{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:51:32Z","timestamp":1788457892438,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Aventis Deutschland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0229-y","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:36:46Z","timestamp":1530664606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations"],"prefix":"10.1186","volume":"19","author":[{"given":"Peter","family":"Kardos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Michael","family":"Beeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Sent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Gr\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-8467","authenticated-orcid":false,"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"issue":"Suppl 1","key":"229_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000195270","volume":"51","author":"BG Disse","year":"1987","unstructured":"Disse BG, Ziegler HW. Pharmacodynamic mechanism and therapeutic activity of Ambroxol in animal experiments. Respiration. 1987;51(Suppl 1):15\u201322.","journal-title":"Respiration"},{"key":"229_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1517\/17460441.2011.629646","volume":"6","author":"D Paleari","year":"2011","unstructured":"Paleari D, Rossi GA, Nicolini G, Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 2011;6:1203\u201314. \n                    https:\/\/doi.org\/10.1517\/17460441.2011.629646\n                    \n                  .","journal-title":"Expert Opin Drug Discov"},{"key":"229_CR3","first-page":"557","volume":"13","author":"KM Beeh","year":"2008","unstructured":"Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of Ambroxol. Eur J Med Res. 2008;13:557\u201362.","journal-title":"Eur J Med Res"},{"key":"229_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","volume":"4","author":"M Malerba","year":"2008","unstructured":"Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4:1119\u201329. \n                    https:\/\/doi.org\/10.1517\/17425255.4.8.1119\n                    \n                  .","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"229_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12272-013-0210-7","volume":"37","author":"M Yamaya","year":"2014","unstructured":"Yamaya M, Nishimura H, Lk N, Ota C, Kubo H, Nagatomi R. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37:520\u20139. \n                    https:\/\/doi.org\/10.1007\/S12272-013-0210-7\n                    \n                  .","journal-title":"Arch Pharm Res"},{"key":"229_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4110\/in.2016.16.3.165","volume":"16","author":"K Takeda","year":"2016","unstructured":"Takeda K, Miyahara N, Matsubara S, Taube C, Kitamura K, Hirano A, Tanimoto M, Gelfand EW. Immunomodulatory effects of Ambroxol on airway Hyperresponsiveness and inflammation. Immune Netw. 2016;16:165\u201375. \n                    https:\/\/doi.org\/10.4110\/In.2016.16.3.165\n                    \n                  .","journal-title":"Immune Netw"},{"key":"229_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ceca.2015.10.002","volume":"58","author":"G Fois","year":"2015","unstructured":"Fois G, Hobi N, Felder E, Ziegler A, Miklavc P, Walther P, Radermacher P, Haller T, Dietl P. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via Ph-dependent Ca2+ release from acidic Ca2+ stores. Cell Calcium. 2015;58:628\u201337. \n                    https:\/\/doi.org\/10.1016\/J.Ceca.2015.10.002","journal-title":"Cell Calcium"},{"key":"229_CR8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A Mcneill","year":"2014","unstructured":"Mcneill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, et al. Ambroxol improves lysosomal biochemistry in Glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137:1481\u201395. \n                    https:\/\/doi.org\/10.1093\/Brain\/Awu020\n                    \n                  .","journal-title":"Brain"},{"key":"229_CR9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuropharm.2005.08.004","volume":"49","author":"W Gaida","year":"2005","unstructured":"Gaida W, Klinder K, Arndt K, Weiser T. Ambroxol, a Nav1.8-Preferring Na+ Channel Blocker, Effectively Suppresses Pain Symptoms In Animal Models Of Chronic, Neuropathic And Inflammatory Pain. Neuropharmacol. 2005;49:1220\u20137. \n                    https:\/\/doi.org\/10.1016\/J.Neuropharm.2005.08.004","journal-title":"Neuropharmacol"},{"key":"229_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2009.12.027","volume":"630","author":"A Leffler","year":"2010","unstructured":"Leffler A, Reckzeh J, Nau C. Block of sensory neuronal Na+ channels by the Secreolytic Ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010;630:19\u201328. \n                    https:\/\/doi.org\/10.1016\/J.Ejphar.2009.12.027","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"229_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000195274","volume":"51","author":"D Olivieri","year":"1987","unstructured":"Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, Carnimeo N, Chianese R, Catena E, Marcatili S, et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Respiration. 1987;51(Suppl 1):42\u201351.","journal-title":"Respiration"},{"key":"229_CR12","first-page":"715","volume":"42","author":"UH Cegla","year":"1988","unstructured":"Cegla UH. Long-term therapy over 2 years with Ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Prax Klin Pneumol. 1988;42:715\u201321.","journal-title":"Prax Klin Pneumol"},{"key":"229_CR13","first-page":"700","volume":"50","author":"H Matthys","year":"2000","unstructured":"Matthys H, De Mey C, Carls C, Rys A, Geib A, Wittig T. Efficacy and tolerability of Myrtol standardized in acute bronchitis. A multi-Centre, randomised, double-blind, placebo-controlled parallel group trial vs. cefuroxime and Ambroxol. Arzneimittelforschung. 2000;50:700\u201311.","journal-title":"Arzneimittelforschung"},{"key":"229_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1055\/S-0031-1296557","volume":"58","author":"C De Mey","year":"2008","unstructured":"De Mey C, Peil H, K\u00f6lsch S, Bubeck J, Vix J-M. Efficacy and safety of Ambroxol lozenges in the treatment of acute uncomplicated sore throat. Arzneimittelforschung. 2008;58:557\u201368. \n                    https:\/\/doi.org\/10.1055\/S-0031-1296557\n                    \n                  .","journal-title":"Arzneimittelforschung"},{"key":"229_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.resp.2005.10.004","volume":"152","author":"R Eccles","year":"2006","unstructured":"Eccles R. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol Neurobiol. 2006;152:340\u20138. \n                    https:\/\/doi.org\/10.1016\/J.Resp.2005.10.004","journal-title":"Respir Physiol Neurobiol"},{"key":"229_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1055\/s-0034-1377332","volume":"68","author":"P Kardos","year":"2014","unstructured":"Kardos P, Lehrl S, Kamin W, Matthys H. Assessment of the effect of pharmacotherapy in common cold\/acute bronchitis \u2013 the bronchitis severity scale (Bss). Pneumologie. 2014;68:542\u20136. \n                    https:\/\/doi.org\/10.1055\/S-0034-1377332\n                    \n                  .","journal-title":"Pneumologie"},{"key":"229_CR17","doi-asserted-by":"publisher","first-page":"00016","DOI":"10.15406\/Jlprr.2014.01.00016","volume":"1","author":"S Lehrl","year":"2014","unstructured":"Lehrl S, Matthys H, Kamin W, Kardos P. The Bss - a valid clinical instrument to measure the severity of acute bronchitis. J Lung Pulmon Resp Res. 2014;1:00016. \n                    https:\/\/doi.org\/10.15406\/Jlprr.2014.01.00016\n                    \n                  .","journal-title":"J Lung Pulmon Resp Res"},{"key":"229_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00210-014-1037-6","volume":"387","author":"HJ Motulsky","year":"2014","unstructured":"Motulsky HJ. Common misconceptions about data analysis and statistics. Naunyn Schmiedeberg's Arch Pharmacol. 2014;387:1017\u201323. \n                    https:\/\/doi.org\/10.1007\/S00210-014-1037-6\n                    \n                  .","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"229_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fmed.2016.00002","volume":"3","author":"P Kardos","year":"2016","unstructured":"Kardos P, Sch\u00fctt T, M\u00fcck T, Schumacher H, Michel MC. Pathophysiological Factors In The Relationship Between Chronological Age And Calculated Lung Age As Detected In A Screening Setting In Community-Dwelling Subjects. Front Med. 2016;3:2. \n                    https:\/\/doi.org\/10.3389\/Fmed.2016.00002\n                    \n                  .","journal-title":"Front Med"},{"key":"229_CR20","doi-asserted-by":"publisher","first-page":"E12907","DOI":"10.1111\/ijcp.12907","volume":"71","author":"L Klimek","year":"2017","unstructured":"Klimek L, Schumacher H, Sch\u00fctt T, Gr\u00e4ter H, M\u00fcck T, Michel MC. Factors Associated With Efficacy Of An Ibuprofen\/Pseudoephedrine Combination Drug In Pharmacy Customers With Common Cold Symptoms. Int J Clin Pract. 2017;71:E12907. \n                    https:\/\/doi.org\/10.1111\/Ijcp.12907\n                    \n                  .","journal-title":"Int J Clin Pract"},{"key":"229_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1023\/A:1007311912777","volume":"13","author":"RE Dales","year":"1997","unstructured":"Dales RE, White J, Bhumgara C, Mcmullen E. Parental reporting of Children\u2019s Coughin is biased. Eur J Epidemiol. 1997;13:541\u20135.","journal-title":"Eur J Epidemiol"},{"key":"229_CR22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaci.2014.08.036","volume":"135","author":"S Anderson-James","year":"2015","unstructured":"Anderson-James S, Newcombe PA, Marchant JM, O'grady KA, Acworth JP, Stone DG, Turner CT, Chang AB. An acute cough-specific quality-of-life questionnaire for children: development and validation. J Allergy Clin Immunol. 2015;135:1179\u201385.E1174. \n                    https:\/\/doi.org\/10.1016\/J.Jaci.2014.08.036\n                    \n                  .","journal-title":"J Allergy Clin Immunol"},{"key":"229_CR23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1183\/09031936.94.07071246","volume":"7","author":"J Hsu","year":"1994","unstructured":"Hsu J, Stone R, Logan-Sinclair R, Worsdell M, Busst C, Chung K. Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J. 1994;7:1246\u201353.","journal-title":"Eur Respir J"},{"key":"229_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/pupt.2002.0364","volume":"15","author":"R Eccles","year":"2002","unstructured":"Eccles R. The powerful placebo in cough studies? Pulm Pharmacol Ther. 2002;15:303\u20138. \n                    https:\/\/doi.org\/10.1006\/Pupt.2002.0364","journal-title":"Pulm Pharmacol Ther"},{"key":"229_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.5414\/CP202156","volume":"52","author":"B Jiang","year":"2014","unstructured":"Jiang B, Chen J-L, Lou H-G, Yu L-Y, Shen H-H, Ruan ZR. Pharmacokinetic and bioequivalence study of three oral formulations of Ambroxol 30 mg: a randomized, three-period crossover comparison in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52:920\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"229_CR26","first-page":"469","volume":"16","author":"G Fan","year":"2000","unstructured":"Fan G, Hu J, Lin M, An D. Multiple dose pharmacokinetics and relative bioavailability in the human body of orally administered Ambroxol hydrochloride Systained-release capsules. Chin Pharmacol Bull. 2000;16:469\u201371.","journal-title":"Chin Pharmacol Bull"},{"key":"229_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00044011-200323040-00007","volume":"23","author":"M Rojpibulstit","year":"2003","unstructured":"Rojpibulstit M, Kasiwong S, Juthong S, Phadoongsombat N, Faroongsarng D. Ambroxol lozenge bioavailability. Clin Drug Investig. 2003;23:273\u201380. \n                    https:\/\/doi.org\/10.2165\/00044011-200323040-00007\n                    \n                  .","journal-title":"Clin Drug Investig"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0229-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0229-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0229-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T14:43:58Z","timestamp":1568904238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0229-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0229-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"18 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This survey did not classify as clinical study based on \u00a740 and \u00a742 of the applicable German law (\u201cArzneimittelgesetz\u201d). According to \u00a767 Abs. 6 it also does not classify as non-interventional study, as that paragraph is strictly focused on prescription medicines. Therefore, and in line with the algorithm provided in EurdaLex volume 10 \u2013 Clinical Trial Guidelines, Boehringer Ingelheim classified the anonymous survey as non-trial activity based on SOP 001-MCS-90-118 (dated 2014). Accordingly, ethical committee approval was neither required nor recommended in Germany for an anonymous survey at the time it was performed. The authors concur with this assessment.According to survey design, customers having purchased one of the four products were invited by the pharmacist to participate in the anonymous survey. Based on the anonymous nature of the survey, no formal consent was obtained but participation was taken as consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In the last 5\u00a0years, PK served on advisory boards for AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Novartis, Takeda and Teva; received lecture fees from AstraZeneca, Boehringer Ingelheim, Cipla, Menarini, Novartis and Teva; participated in sponsored clinical trials from AstraZeneca, Boehringer Ingelheim and Novartis and has been reimbursed for attending scientific symposia from AstraZeneca, Boehringer Ingelheim, Menarini and Novartis.KMB declares that no personal payments were received from any pharmaceutical entity in the past 5\u00a0years. KMB is a full-time employee of insaf Respiratory Research Institute. His institution has received compensation for services on advisory boards or consulting for Ablynx, Almirall, AstraZeneca, Berlin Chemie, Boehringer, Chiesi, Cytos, Mundipharma, Novartis, Pohl Boskamp, Zentiva. His institution has received compensation for speaker activities in scientific meetings supported by Almirall, AstraZeneca, Berlin Chemie, Boehringer, Cytos, ERT, GSK, Novartis, Pfizer, Pohl Boskamp, Takeda. The institution has further received compensation for design and performance of clinical trials from Almirall, Altana\/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, MSD, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Revotar, Teva, Sterna, and Zentiva.US, TM and HG are employees of Sanofi Aventis.MCM is a past employee of Boehringer Ingelheim and currently a consultant to Sanofi-Aventis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}